Small molecule · Inhibitor of AKT1, AKT2 and AKT3 · developed by Astrazeneca
Capivasertib is an orally available pyrrolopyrimidine inhibitor of all three AKT isoforms (AKT1, AKT2 and AKT3), blocking phosphorylation of downstream AKT substrates in the PI3K/AKT pathway. It is studied in breast cancer, including triple-negative and PIK3CA-mutated disease, and in prostate cancer.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 12, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06982521 | Phase 3 | PIK3CA Mutation | Recruiting | RLAY |
| NCT03742102 | Phase 1/2 | Triple Negative Breast Neoplasms | Active not recruiting | AZN |
| NCT01992952 | Phase 1/2 | Estrogen Receptor Positive Breast Cancer | Active not recruiting | CRDF |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Breast CancerBreast CancerEstrogen Receptor Positive Breast CancerHER2- Negative Breast CancerHormone Receptor Positive TumorMetastatic Breast CancerPIK3CA MutationTriple Negative Breast Neoplasms
Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →